Notification of trade among primary insiders
Reference is made to the notice to the stock exchange on 3 November 2010 regarding commencement of subscription period for the “Subsequent repair offering”. On 16 November 2010 mandatory notification of trade among primary insiders of DiaGenic ASA took place. The transactions are described in detail below.
Atul Shah, board member in DiaGenic ASA, has through a related company received 2,006,377 subscription rights in the subsequent repair issue. Shah’s related company has subscribed for 5,006,377 shares in the subsequent repair offering at NOK 0.50 per share. Shah’s indirect holding in the Company will increase from 1,877,224 shares to minimum 3,883,601 shares and maximum 6,883,601 shares post allotment of the shares in the offering.
Praveen Sharma, director and board member in DiaGenic ASA, has received 2,662,128 subscription rights in the subsequent repair issue. Sharma has sold 2,662,128 subscription rights to related company Capveen AS at NOK 0.09 per subscription right. Subsequently Sharma has through Capveen AS subscribed for 2,662,128 shares in the subsequent repair offering at NOK 0.50 per share. Sharma’s direct and indirect holding in the Company will increase from 2,490,764 shares to 5,152,892 shares post allotment of the shares in the offering.
Dag Christian Christiansen, director in DiaGenic ASA, has received 235,136 subscription rights in the subsequent repair issue. Christiansen has subscribed for 250,000 shares in the subsequent repair offering at NOK 0.50 per share. Christiansen holding in the Company will increase from 220,000 shares to minimum 455,136 shares and maximum 470,000 shares post allotment of the shares in the offering.
Contact:
Erik Christensen, CEO
Telephone: 47 95939918
e-mail: erik.christensen@diagenic.com
About DiaGenic ASA
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com